EUCTR2006-004286-33-PL进行中（未招募）1 期
An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spansms.
Marinus Pharmceuticals, Inc.0 个研究点目标入组 54 人开始时间: 2007年6月4日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a) Have completed all scheduled clinical study visits in the previous Protocol 1042-0500 and have been deemed eligible (no SAEs thought to be drug related and had a response to treatment) by the Investigator.
- •b) Be diagnosed with IS after electroencephalogram (EEG) evaluations (regardless of etiology- except for a progressive neurologic illness, see protocol Section 9.3.3 Exclusion Criteria). Diagnostic Criteria: Seizures consisting of single or repetitive short muscular contractions leading to flexion or extension. Spasms may be characterized as tonic or myoclonic contractions, may occur singly or in clusters, and typically occur bilaterally and symmetrically. The EEG pattern must be consistent with the diagnosis of IS (hypsarrhythmia, modified hypsarrhythmia, multifocal spike wave discharges, etc).
- •c) Have a 24-hour vEEG recording confirming the diagnosis of IS.
- •d) Have had a magnetic resonance imaging (MRI) performed to determine any possible causes of IS.
- •e) Have been previously treated with 3 AEDs or fewer.
- •f) Have a parent/guardian who is properly informed of the nature and potential risks and benefits of the clinical study, is willing and capable of complying with all clinical study procedures, and has given informed consent in writing prior to entering the clinical study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a) Current treatment with more than 2 concomitant AEDs.
- •b) Have an active CNS infection, demyelinating disease, degenerative neurological disease, or CNS disease deemed progressive (with the exception of tuberous sclerosis) as evaluated by brain MRI.
- •c) Have any disease or condition (medical or surgical) at Screening that might compromise the hematologic, cardiovascular, pulmonary, renal, GI, or hepatic systems; or other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the investigational product, or would place the subject at increased risk.
- •d) Aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin greater than 4 times the upper limit of laboratory normal or any clinical laboratory value deemed clinically significant by the Investigator.
- •e) History of recurrent status epilepticus.
- •f) Have been exposed to any other investigational drug within 30 days prior to enrollment.
研究者
相似试验
进行中（未招募）
不适用
An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spasms.EUCTR2006-004286-33-CZMarinus Pharmceuticals, Inc.54
尚未招募
4 期
How Maxvida High-Protein Formula Affects Adults Needing Tube Feeding with the Same CaloriesCTRI/2024/06/068511Signtura Health and nutrition
已完成
不适用
A clinical study to evaluate the glycemic index (glucose level in blood in 2 Hour period) and safety of COCOZEN in Human Volunteers.CTRI/2018/03/012389Akay Flavours and Aromatics Private Limited20
尚未招募
4 期
Clinical efficacy and safety of Isha BalmCTRI/2018/02/011819Isha Arogya pvt ltd
已完成
不适用
CelWel in Long CovidCTRI/2022/12/048144Carmel Research Consultancy Private Limited15